Skip to main content
Equibles

Biren Amin

Analyst

Piper Sandler

CFO

Immuneering Corp (IMRX)

Equibles does not estimate personal net worth.

About Biren Amin

Biren Amin is recorded as Analyst at Piper Sandler and CFO at Immuneering Corp (IMRX). The newest filing on record that lists Biren Amin as CFO at Immuneering Corp (IMRX) is dated May 2, 2022. The proxy statement of Immuneering Corp reports total compensation of $3,273,530 for Biren Amin in fiscal 2021, including a base salary of $312,500. Disclosed compensation is on record for 2 fiscal years. Biren Amin has spoken on 2 earnings calls and 1 other investor event across 2 companies, most recently for BridgeBio Pharma, Inc. on October 29, 2026. Those appearances were for Taysha Gene Therapies, Inc. (TSHA) and BridgeBio Pharma, Inc. (BBIO). Immuneering Corp is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Biren Amin spoke on are classified in the Healthcare sector. Other leadership on record at Immuneering Corp includes Benjamin Zeskind (CEO and Board Member), Andrew Gengos (CFO), Michael D. Bookman (General Counsel) and 4 others.

Biren Amin on recent calls

“You've got about $1.5 billion of cash and three product launches in the near term. How should we think about funding needs of a Truby and the new launches, and do you have what you need to get the profitability with the current balance sheet?”
Analyst — Piper Sandler, BridgeBio Q3 Earnings Call ·
“I'd like to get your view regarding to what degree will long-term data from Part A be part of FDA's consideration on accepting the six-month interim from Part B. And then given, you know, these data updates on long-term durability, will you be applying for CMPV?”
Analyst — Piper Sandler, TSHA-102 Rett Syndrome Program Update Conference Call ·
“Recently, the FDA commissioner announced the real-time clinical monitoring program that enables the FDA to evaluate data real-time.”
Analyst — Piper Sandler, Taysha Gene Therapies, Inc. Q1 FY2026 Earnings Call ·

Affiliation history

  • Piper Sandler

    Analyst

    Source not stated

    Current
  • Immuneering Corp (IMRX)

    CFO

    Proxy statement

    Current

    Start not stated–present

    Last confirmed May 2, 2022

Company network

Leadership on record at Immuneering Corp

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2021 Immuneering Corp (IMRX) $312,500 $3,273,530
2020 Immuneering Corp (IMRX) — —

Recent activity